Vamorolone is an anti-inflammatory drug being developed by SME ReveraGen Biopharma. This unique and innovative drug development programme has used a Venture Philanthropy funding model with patient groups and grants from the US and Europe. The ambition is to deliver a safe, effective drug for the treatment of Duchenne Muscular Dystrophy to halt the progress of the disease and increase muscle strength.

Ceratium developed the project strategy and produced the successful proposal working closely with ReveraGen (US & UK) and The University of Newcastle’s John Walton Muscular Dystrophy Research Centre (UK) who coordinate the project. The project undertakes Phase 2 clinical trials in Europe, the US and Australia. Partners include World Duchenne Organisation (NL), formerly the United Parent Projects Muscular Dystrophy, a worldwide reaching patient group bringing expert guidance and patient engagement to the project; The University Hospital Motol (CZ) who offer specialist expertise and our team at Ceratium Ltd who oversee project management and impact. For more information visit: www.vision-dmd.info